The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex Life Sciences” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Anavex Life Sciences announced on February 1, 2022, that its Phase 3 trial of drug candidate ANAVEX2-73 (blarcamesine) met primary and secondary endpoints for the treatment of Rett syndrome. Following this announcement, the Company faced questions about the validity of the Phase 3 trial on social media. For example, Adam Feuerstein, senior writer on Biotech for STAT, tweeted: “Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed.” Based on this news, shares of Anavex Life Sciences dropped sharply on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005793/en/